Epstein-Barr virus and CD21 expression in gastrointestinal tumors

Young Sik Kim, Seung R. Paik, Han Kyeom Kim, Bom Woo Yeom, Insun Kim, Dale Lee

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Epstein-Barr virus (EBV) was found in 7-17% of gastric adenocarcinomas, including lymphoepitheliomalike carcinomas, although its significance has not been clear. In addition, 20-30% of malignant lymphomas arising in the gastrointestinal tract have been known to express the EBV genome. Several lines of evidence indicate that EBV has been shown to infect both B lymphocytes and squamous epithelial cells via CD21 molecule in vivo and in vitro. The expression of CD21 in EBV-associated gastrointestinal tumors, however, has remained controversial. To determine the presence of CD21, an EBV receptor, in the EBV-associated gastrointestinal tumors, we, first, examined the EBV genome in sixty seven patients with either gastrointestinal adenocarcinomas or malignant lymphomas using in situ hybridization (ISH) for EBV-encoded small RNAs (EBERs) and PCR for EBNA-1. Then, the investigation of CD21 expression was performed only in the EBV-positive tumors with immunohistochemical method for CD21 antigen on paraffin sections. EBERs were detected in 6 out of 26 gastric adenocarcinomas, 2 of 24 colonic adenocarcinomas, and 8 of 17 malignant lymphomas. EBERs were more prevalent in the malignant lymphomas originating from the small and large intestine (6/6) than from the stomach (2/11), and were detected in both B and T cell phenotypes. EBNA-1 was amplified in 11 of 16 EBERs-positive cases. Interestingly, however, none of the EBV-positive six gastric adenocarcinomas and eight malignant lymphomas expressed the CD21 on the cell surfaces or cytoplasm of both tumor cells and adjacent normal epithelial cells. These results suggest that EBV infection in the gastrointestinal malignancies would be mediated via different routes besides the CD21 or a new receptor distinct from CD21.

Original languageEnglish
Pages (from-to)705-711
Number of pages7
JournalPathology Research and Practice
Volume194
Issue number10
Publication statusPublished - 1998 Nov 28

Fingerprint

Human Herpesvirus 4
Neoplasms
Lymphoma
Adenocarcinoma
Stomach
Complement 3d Receptors
RNA
B-Lymphocytes
Epithelial Cells
Genome
Epstein-Barr Virus Infections
Large Intestine
Paraffin
Small Intestine
In Situ Hybridization
Gastrointestinal Tract
Cytoplasm
Carcinoma
T-Lymphocytes
Phenotype

Keywords

  • Adenocarcinoma
  • CD21
  • Epstein-Barr virus
  • Gastrointestinal tract
  • Malignant lymphoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Epstein-Barr virus and CD21 expression in gastrointestinal tumors. / Kim, Young Sik; Paik, Seung R.; Kim, Han Kyeom; Yeom, Bom Woo; Kim, Insun; Lee, Dale.

In: Pathology Research and Practice, Vol. 194, No. 10, 28.11.1998, p. 705-711.

Research output: Contribution to journalArticle

Kim, YS, Paik, SR, Kim, HK, Yeom, BW, Kim, I & Lee, D 1998, 'Epstein-Barr virus and CD21 expression in gastrointestinal tumors', Pathology Research and Practice, vol. 194, no. 10, pp. 705-711.
Kim, Young Sik ; Paik, Seung R. ; Kim, Han Kyeom ; Yeom, Bom Woo ; Kim, Insun ; Lee, Dale. / Epstein-Barr virus and CD21 expression in gastrointestinal tumors. In: Pathology Research and Practice. 1998 ; Vol. 194, No. 10. pp. 705-711.
@article{8bb3bcb707b945918507b30936e6c021,
title = "Epstein-Barr virus and CD21 expression in gastrointestinal tumors",
abstract = "Epstein-Barr virus (EBV) was found in 7-17{\%} of gastric adenocarcinomas, including lymphoepitheliomalike carcinomas, although its significance has not been clear. In addition, 20-30{\%} of malignant lymphomas arising in the gastrointestinal tract have been known to express the EBV genome. Several lines of evidence indicate that EBV has been shown to infect both B lymphocytes and squamous epithelial cells via CD21 molecule in vivo and in vitro. The expression of CD21 in EBV-associated gastrointestinal tumors, however, has remained controversial. To determine the presence of CD21, an EBV receptor, in the EBV-associated gastrointestinal tumors, we, first, examined the EBV genome in sixty seven patients with either gastrointestinal adenocarcinomas or malignant lymphomas using in situ hybridization (ISH) for EBV-encoded small RNAs (EBERs) and PCR for EBNA-1. Then, the investigation of CD21 expression was performed only in the EBV-positive tumors with immunohistochemical method for CD21 antigen on paraffin sections. EBERs were detected in 6 out of 26 gastric adenocarcinomas, 2 of 24 colonic adenocarcinomas, and 8 of 17 malignant lymphomas. EBERs were more prevalent in the malignant lymphomas originating from the small and large intestine (6/6) than from the stomach (2/11), and were detected in both B and T cell phenotypes. EBNA-1 was amplified in 11 of 16 EBERs-positive cases. Interestingly, however, none of the EBV-positive six gastric adenocarcinomas and eight malignant lymphomas expressed the CD21 on the cell surfaces or cytoplasm of both tumor cells and adjacent normal epithelial cells. These results suggest that EBV infection in the gastrointestinal malignancies would be mediated via different routes besides the CD21 or a new receptor distinct from CD21.",
keywords = "Adenocarcinoma, CD21, Epstein-Barr virus, Gastrointestinal tract, Malignant lymphoma",
author = "Kim, {Young Sik} and Paik, {Seung R.} and Kim, {Han Kyeom} and Yeom, {Bom Woo} and Insun Kim and Dale Lee",
year = "1998",
month = "11",
day = "28",
language = "English",
volume = "194",
pages = "705--711",
journal = "Pathology Research and Practice",
issn = "0344-0338",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "10",

}

TY - JOUR

T1 - Epstein-Barr virus and CD21 expression in gastrointestinal tumors

AU - Kim, Young Sik

AU - Paik, Seung R.

AU - Kim, Han Kyeom

AU - Yeom, Bom Woo

AU - Kim, Insun

AU - Lee, Dale

PY - 1998/11/28

Y1 - 1998/11/28

N2 - Epstein-Barr virus (EBV) was found in 7-17% of gastric adenocarcinomas, including lymphoepitheliomalike carcinomas, although its significance has not been clear. In addition, 20-30% of malignant lymphomas arising in the gastrointestinal tract have been known to express the EBV genome. Several lines of evidence indicate that EBV has been shown to infect both B lymphocytes and squamous epithelial cells via CD21 molecule in vivo and in vitro. The expression of CD21 in EBV-associated gastrointestinal tumors, however, has remained controversial. To determine the presence of CD21, an EBV receptor, in the EBV-associated gastrointestinal tumors, we, first, examined the EBV genome in sixty seven patients with either gastrointestinal adenocarcinomas or malignant lymphomas using in situ hybridization (ISH) for EBV-encoded small RNAs (EBERs) and PCR for EBNA-1. Then, the investigation of CD21 expression was performed only in the EBV-positive tumors with immunohistochemical method for CD21 antigen on paraffin sections. EBERs were detected in 6 out of 26 gastric adenocarcinomas, 2 of 24 colonic adenocarcinomas, and 8 of 17 malignant lymphomas. EBERs were more prevalent in the malignant lymphomas originating from the small and large intestine (6/6) than from the stomach (2/11), and were detected in both B and T cell phenotypes. EBNA-1 was amplified in 11 of 16 EBERs-positive cases. Interestingly, however, none of the EBV-positive six gastric adenocarcinomas and eight malignant lymphomas expressed the CD21 on the cell surfaces or cytoplasm of both tumor cells and adjacent normal epithelial cells. These results suggest that EBV infection in the gastrointestinal malignancies would be mediated via different routes besides the CD21 or a new receptor distinct from CD21.

AB - Epstein-Barr virus (EBV) was found in 7-17% of gastric adenocarcinomas, including lymphoepitheliomalike carcinomas, although its significance has not been clear. In addition, 20-30% of malignant lymphomas arising in the gastrointestinal tract have been known to express the EBV genome. Several lines of evidence indicate that EBV has been shown to infect both B lymphocytes and squamous epithelial cells via CD21 molecule in vivo and in vitro. The expression of CD21 in EBV-associated gastrointestinal tumors, however, has remained controversial. To determine the presence of CD21, an EBV receptor, in the EBV-associated gastrointestinal tumors, we, first, examined the EBV genome in sixty seven patients with either gastrointestinal adenocarcinomas or malignant lymphomas using in situ hybridization (ISH) for EBV-encoded small RNAs (EBERs) and PCR for EBNA-1. Then, the investigation of CD21 expression was performed only in the EBV-positive tumors with immunohistochemical method for CD21 antigen on paraffin sections. EBERs were detected in 6 out of 26 gastric adenocarcinomas, 2 of 24 colonic adenocarcinomas, and 8 of 17 malignant lymphomas. EBERs were more prevalent in the malignant lymphomas originating from the small and large intestine (6/6) than from the stomach (2/11), and were detected in both B and T cell phenotypes. EBNA-1 was amplified in 11 of 16 EBERs-positive cases. Interestingly, however, none of the EBV-positive six gastric adenocarcinomas and eight malignant lymphomas expressed the CD21 on the cell surfaces or cytoplasm of both tumor cells and adjacent normal epithelial cells. These results suggest that EBV infection in the gastrointestinal malignancies would be mediated via different routes besides the CD21 or a new receptor distinct from CD21.

KW - Adenocarcinoma

KW - CD21

KW - Epstein-Barr virus

KW - Gastrointestinal tract

KW - Malignant lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0031727410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031727410&partnerID=8YFLogxK

M3 - Article

C2 - 9820867

AN - SCOPUS:0031727410

VL - 194

SP - 705

EP - 711

JO - Pathology Research and Practice

JF - Pathology Research and Practice

SN - 0344-0338

IS - 10

ER -